Showing results (141-150 of 218) with videos related to
Sort By:
Pageof 22
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 6, 2019
First-in-Humans Imaging with <sup>89</sup>Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion TargetingNeeta Pandit-Taskar, Michael A Postow, Matthew D Hellmann, et al.The Journal of Experimental Medicine|December 22, 2021
TCR signal strength defines distinct mechanisms of T cell dysfunction and cancer evasionMojdeh Shakiba, Paul Zumbo, Gabriel Espinosa-Carrasco, et al.The Journal of Experimental Medicine|May 23, 2022
Tumor-induced double positive T cells display distinct lineage commitment mechanisms and functionsSara E Schad, Andrew Chow, Levi Mangarin, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 29, 2019
Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumorsM D Hellmann, T-W Kim, C B Lee, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 26, 2020
The Genomic Landscape of <i>SMARCA4</i> Alterations and Associations with Outcomes in Patients with Lung CancerAdam J Schoenfeld, Chai Bandlamudi, Jessica A Lavery, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 22, 2022
Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysisH Borghaei, T-E Ciuleanu, J-S Lee, et al.Journal for Immunotherapy of Cancer|May 31, 2022
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesotheliomaRamaswamy Govindan, Charu Aggarwal, Scott J Antonia, et al.JCO Precision Oncology|December 14, 2019
Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non-Small-Cell Lung CancerNatalie I Vokes, David Liu, Biagio Ricciuti, et al.Journal for Immunotherapy of Cancer|July 18, 2018
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)Julie R Brahmer, Ramaswamy Govindan, Robert A Anders, et al.The New England Journal of Medicine|April 17, 2018
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational BurdenMatthew D Hellmann, Tudor-Eliade Ciuleanu, Adam Pluzanski, et al.Pageof 22